These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

443 related items for PubMed ID: 15857303

  • 1. Poly (adp-ribose) polymerase inhibitors as potential therapeutic agents in stroke and neurotrauma.
    Komjáti K, Besson VC, Szabó C.
    Curr Drug Targets CNS Neurol Disord; 2005 Apr; 4(2):179-94. PubMed ID: 15857303
    [Abstract] [Full Text] [Related]

  • 2. The therapeutic potential of poly(ADP-ribose) polymerase inhibitors.
    Virág L, Szabó C.
    Pharmacol Rev; 2002 Sep; 54(3):375-429. PubMed ID: 12223530
    [Abstract] [Full Text] [Related]

  • 3. Structure and function of poly(ADP-ribose) polymerase-1: role in oxidative stress-related pathologies.
    Virág L.
    Curr Vasc Pharmacol; 2005 Jul; 3(3):209-14. PubMed ID: 16026317
    [Abstract] [Full Text] [Related]

  • 4. Poly(ADP-ribose) polymerase inhibitors.
    Southan GJ, Szabó C.
    Curr Med Chem; 2003 Feb; 10(4):321-40. PubMed ID: 12570705
    [Abstract] [Full Text] [Related]

  • 5. Alternative mechanisms of inhibiting activity of poly (ADP-ribose) polymerase-1.
    Sriram CS, Jangra A, Bezbaruah BK, V AK, Sykam S.
    Front Biosci (Schol Ed); 2016 Jan 01; 8(1):123-8. PubMed ID: 26709902
    [Abstract] [Full Text] [Related]

  • 6. Poly(ADP-ribose) Polymerase (PARP) and PARP Inhibitors: Mechanisms of Action and Role in Cardiovascular Disorders.
    Henning RJ, Bourgeois M, Harbison RD.
    Cardiovasc Toxicol; 2018 Dec 01; 18(6):493-506. PubMed ID: 29968072
    [Abstract] [Full Text] [Related]

  • 7. Poly (ADP-ribose) polymerase: An Overview of Mechanistic Approaches and Therapeutic Opportunities in the Management of Stroke.
    Tiwari P, Khan H, Singh TG, Grewal AK.
    Neurochem Res; 2022 Jul 01; 47(7):1830-1852. PubMed ID: 35437712
    [Abstract] [Full Text] [Related]

  • 8. A novel and potent poly(ADP-ribose) polymerase-1 inhibitor, FR247304 (5-chloro-2-[3-(4-phenyl-3,6-dihydro-1(2H)-pyridinyl)propyl]-4(3H)-quinazolinone), attenuates neuronal damage in in vitro and in vivo models of cerebral ischemia.
    Iwashita A, Tojo N, Matsuura S, Yamazaki S, Kamijo K, Ishida J, Yamamoto H, Hattori K, Matsuoka N, Mutoh S.
    J Pharmacol Exp Ther; 2004 Aug 01; 310(2):425-36. PubMed ID: 15075382
    [Abstract] [Full Text] [Related]

  • 9. Inhibitors of poly(ADP-ribose) polymerase modulate signal transduction pathways and secondary damage in experimental spinal cord trauma.
    Genovese T, Mazzon E, Muià C, Patel NS, Threadgill MD, Bramanti P, De Sarro A, Thiemermann C, Cuzzocrea S.
    J Pharmacol Exp Ther; 2005 Feb 01; 312(2):449-57. PubMed ID: 15452194
    [Abstract] [Full Text] [Related]

  • 10. Poly(ADP-Ribose) polymerase-1 in acute neuronal death and inflammation: a strategy for neuroprotection.
    Skaper SD.
    Ann N Y Acad Sci; 2003 May 01; 993():217-28; discussion 287-8. PubMed ID: 12853316
    [Abstract] [Full Text] [Related]

  • 11. Modulating poly (ADP-ribose) polymerase activity: potential for the prevention and therapy of pathogenic situations involving DNA damage and oxidative stress.
    Decker P, Muller S.
    Curr Pharm Biotechnol; 2002 Sep 01; 3(3):275-83. PubMed ID: 12164482
    [Abstract] [Full Text] [Related]

  • 12. Poly(ADP-ribose) polymerase inhibitors: new pharmacological functions and potential clinical implications.
    de la Lastra CA, Villegas I, Sánchez-Fidalgo S.
    Curr Pharm Des; 2007 Sep 01; 13(9):933-62. PubMed ID: 17430191
    [Abstract] [Full Text] [Related]

  • 13. Poly(ADP-ribose)polymerase 1 (PARP-1) and postischemic brain damage.
    Moroni F.
    Curr Opin Pharmacol; 2008 Feb 01; 8(1):96-103. PubMed ID: 18032109
    [Abstract] [Full Text] [Related]

  • 14. Ischemic brain injury is mediated by the activation of poly(ADP-ribose)polymerase.
    Endres M, Wang ZQ, Namura S, Waeber C, Moskowitz MA.
    J Cereb Blood Flow Metab; 1997 Nov 01; 17(11):1143-51. PubMed ID: 9390645
    [Abstract] [Full Text] [Related]

  • 15. Mediation of cell death by poly(ADP-ribose) polymerase-1.
    Koh DW, Dawson TM, Dawson VL.
    Pharmacol Res; 2005 Jul 01; 52(1):5-14. PubMed ID: 15911329
    [Abstract] [Full Text] [Related]

  • 16. Natural inhibitors of poly(ADP-ribose) polymerase-1.
    Banasik M, Stedeford T, Strosznajder RP.
    Mol Neurobiol; 2012 Aug 01; 46(1):55-63. PubMed ID: 22476980
    [Abstract] [Full Text] [Related]

  • 17. NAD+ as a metabolic link between DNA damage and cell death.
    Ying W, Alano CC, Garnier P, Swanson RA.
    J Neurosci Res; 2012 Aug 01; 79(1-2):216-23. PubMed ID: 15562437
    [Abstract] [Full Text] [Related]

  • 18. Pathophysiologic role of oxidative stress-induced poly(ADP-ribose) polymerase-1 activation: focus on cell death and transcriptional regulation.
    Erdélyi K, Bakondi E, Gergely P, Szabó C, Virág L.
    Cell Mol Life Sci; 2005 Apr 01; 62(7-8):751-9. PubMed ID: 15868400
    [Abstract] [Full Text] [Related]

  • 19. Drug targets for traumatic brain injury from poly(ADP-ribose)polymerase pathway modulation.
    Besson VC.
    Br J Pharmacol; 2009 Jul 01; 157(5):695-704. PubMed ID: 19371326
    [Abstract] [Full Text] [Related]

  • 20. Role of Peroxynitrite-Induced Activation of Poly(ADP-Ribose) Polymerase (PARP) in Circulatory Shock and Related Pathological Conditions.
    Islam BU, Habib S, Ali SA, Moinuddin, Ali A.
    Cardiovasc Toxicol; 2017 Oct 01; 17(4):373-383. PubMed ID: 27990620
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.